Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264566 | 0.88 | STAT3 (0.55) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL15688188 | 0.88 | ALDH1A1 (0.56) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL20137410 | 0.79 | MGLL (0.50) | MAPTALDH1A1LMNA | |
| SCHEMBL28325485 | 0.79 | STAT3 (0.42) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| Tert-Butyl Formate SCHEMBL28325487 | 0.79 | MEN1 (0.47) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL6891634 | 0.78 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL25026904 | 0.77 | RAB9A (0.57) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL13678600 | 0.77 | MAPK1 (0.53) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL3152366 | 0.77 | MEN1 (0.58) | MEN1KMT2AMAPTMAOAALDH1A1 | |
| SCHEMBL1264542 | 0.76 | RAB9A (0.43) | MEN1KMT2AMAPTMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | IDO1, RB1, IDO2 | MEN1 1095/4885KMT2A 1237/4885MAPT 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.